The impact of different EPIC regimen use on the postoperative outcome.

How does the postoperative outcome differ in peritoneal surface malignancy after management with CRS and HIPEC + EPIC using Taxol vs. CRS and HIPEC + EPIC using 5-FU?

01 January 1970 9,214 0 View